Legacy Private Trust’s Neumora Therapeutics NMRA Stock Holding History

Legacy Private Trust’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.5K	Buy	25,000 +6,000	+32%	+$11.4K	﹤0.01%	265
2026 Q1	$37K	Hold	19,000	–	–	﹤0.01%	259
2025 Q4	$34K	Buy	19,000 +5,000	+36%	+$10.9K	﹤0.01%	257
2025 Q3	$25.5K	Buy	+14,000	New	+$22.6K	﹤0.01%	256
2025 Q2	–	Sell	-12,000	Closed	-$12K	–	253
2025 Q1	$12K	Buy	12,000 +2,000	+20%	+$3.42K	﹤0.01%	243
2024 Q4	$106K	Hold	10,000	–	–	0.01%	235
2024 Q3	$132K	Hold	10,000	–	–	0.01%	230
2024 Q2	$98.3K	Hold	10,000	–	–	0.01%	226
2024 Q1	$138K	Hold	10,000	–	–	0.01%	225
2023 Q4	$171K	Buy	+10,000	New	+$123K	0.01%	219

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Legacy Private Trust's NMRA Position: Q2 2026 in Review

Legacy Private Trust increased its Neumora Therapeutics (NMRA) stake by 32% in Q2 2026, buying an estimated $11.4K and bringing the position to 25,000 shares worth $42.5K. The position accounts for ﹤0.01% of the portfolio, ranked #265.

Legacy Private Trust first reported a position in NMRA in Q4 2023 and has held it in 10 quarters since. The position peaked at $171K in Q4 2023. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

Legacy Private Trust held 25,000 shares of Neumora Therapeutics worth $42.5K as of Q2 2026.
Legacy Private Trust bought 6,000 Neumora Therapeutics shares in Q2 2026, an estimated $11.4K.
Neumora Therapeutics made up ﹤0.01% of Legacy Private Trust's portfolio in Q2 2026, its #265 holding.
Legacy Private Trust first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 10 quarters since.
Legacy Private Trust's Neumora Therapeutics position peaked at $171K in Q4 2023.
113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Legacy Private Trust's 13F filing for Q2 2026, filed 21 Jul 2026.